



## **ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC**

**Geneva, Switzerland and Boston, MA – 30 August, 2017** – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Company Management will be presenting at the below conferences and also hosting one on one meetings with investors.

- The Baird 2017 Global Healthcare Conference taking place in New York, at the InterContinental New York Barclay, on September 6-7, 2017. Company Management will be presenting on Wednesday September 6, 2017, at 2:00 p.m. Eastern Time.
- The Rodman & Renshaw 19<sup>th</sup> Annual Global Investment Conference taking place in New York, at the Lotte New York Palace, on September 10-12, 2017. Company Management will be presenting on Tuesday September 12, 2017, at 10:25 a.m. Eastern Time.

### **About ObsEva**

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit [www.ObsEva.com](http://www.ObsEva.com).

### **Cautionary Note Regarding Forward Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva's product candidates and the timing of enrollment in and data from clinical trials. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual

results to differ materially include uncertainties inherent in the conduct of clinical trials, ObsEva's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2016, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva's website at <http://www.obseva.com>. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

**Media Contact:**

Liz Bryan  
Spectrum Science  
[lbryan@spectrumscience.com](mailto:lbryan@spectrumscience.com)  
202-955-6222 x2526

**CEO Office contact:**

Delphine Renaud  
[delphine.renaud@obseva.ch](mailto:delphine.renaud@obseva.ch)  
+41 22 552 1550

**Investor Contact:**

Mario Corso  
Senior Director, Investor Relations  
[mario.corso@obseva.com](mailto:mario.corso@obseva.com)  
781-366-5726